NanoViricides (NNVC)
(Real Time Quote from BATS)
$1.61 USD
+0.04 (2.55%)
Updated Sep 23, 2024 12:44 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
NNVC 1.61 +0.04(2.55%)
Will NNVC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NNVC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for NNVC
NanoViricides investigating MEURI protocol for using NV-387 to treat MPOX
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more
NanoViricides provides update on NV-387 pathway
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -???A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections